Sign in Subscribe
Cancer research

CAR-T Cell Therapy Shows Promise in Treating Acute Lymphoblastic Leukemia

Strategic Insights

— 1 min read

Researchers from the Chinese Academy of Medical Sciences have conducted a phase I trial investigating the efficacy of autologous CD7 CAR-T cell therapy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL). The study, which enrolled 30 patients, demonstrated promising results, with 96% of patients responding to the treatment and 85% achieving complete remission or complete remission with incomplete hematologic recovery by day 30.

Key Takeaways:

  • The study evaluated autologous CD7 CAR-T cells manufactured without pre-selection of healthy T cells in patients with refractory or relapsed T-ALL.
  • Thirty patients (29 children and one adult) were enrolled, with a median of two lines of prior therapy.
  • The treatment showed preliminary activity, with 90% of patients receiving infusions after products were confirmed free of leukemia contamination.
  • Common adverse events within 30 days included grade 3-4 cytopenias, cytokine release syndrome, neurotoxicity, infection, and graft-versus-host disease.
  • At day 30, 96% of patients responded to the treatment, and 85% achieved complete remission or CR with incomplete hematologic recovery.
  • Twelve-month progression-free survival with and without censoring transplantation was 22% and 57%, respectively.
  • The study concluded that autologous CD7 CAR-T therapy without T cell pre-selection is feasible in patients with refractory or relapsed T-ALL.

Statistics:

  • 96% of patients responded to the treatment by day 30.
  • 85% of patients achieved complete remission or CR with incomplete hematologic recovery by day 30.
  • 90% of patients received infusions after products were confirmed free of leukemia contamination.
  • 100% of patients experienced grade 3-4 cytopenias as a common adverse event.
  • 7% of patients experienced grade 3-4 cytokine release syndrome.
  • 4% of patients experienced grade 2 infection and grade 2 graft-versus-host disease.
  • 12-month progression-free survival with and without censoring transplantation was 22% and 57%, respectively.

Sources:

  • Autologous Cd7 Car-t Cells Generated Without T Cell Pre-selection In Pediatric Patients With Relapsed/Refactory T-all: a Phase I Trial. Molecular Therapy, 2025;33(6):2753-2767.
  • Chinese Academy of Medical Sciences, State Key Lab Expt Hematol, Institute of Hematology, Natl Clin Res Ctr Blood Dis, Haihe Lab Cell Ecosyst, Tianjin 300020, People's Republic of China.

Read more